Literature DB >> 23576558

FGFR1 is essential for prostate cancer progression and metastasis.

Feng Yang1, Yongyou Zhang, Steven J Ressler, Michael M Ittmann, Gustavo E Ayala, Truong D Dang, Fen Wang, David R Rowley.   

Abstract

The fibroblast growth factor receptor 1 (FGFR1) is ectopically expressed in prostate carcinoma cells, but its functional contributions are undefined. In this study, we report the evaluation of a tissue-specific conditional deletion mutant generated in an ARR2PBi(Pbsn)-Cre/TRAMP/fgfr1(loxP/loxP) transgenic mouse model of prostate cancer. Mice lacking fgfr1, in prostate cells developed smaller tumors that also included distinct cancer foci still expressing fgfr1 indicating focal escape from gene excision. Tumors with confirmed fgfr1 deletion exhibited increased foci of early, well-differentiated cancer and phyllodes-type tumors, and tumors that escaped fgfr1 deletion primarily exhibited a poorly differentiated phenotype. Consistent with these phenotypes, mice carrying the fgfr1 null allele survived significantly longer than those without fgfr1 deletion. Most interestingly, all metastases were primarily negative for the fgfr1 null allele, exhibited high FGFR1 expression, and a neuroendocrine phenotype regardless of fgfr1 status in the primary tumors. Together, these results suggest a critical and permissive role of ectopic FGFR1 signaling in prostate tumorigenesis and particularly in mechanisms of metastasis. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576558      PMCID: PMC3686853          DOI: 10.1158/0008-5472.CAN-12-3274

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.

Authors:  A Mosca; A Berruti; L Russo; M Torta; L Dogliotti
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

2.  FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals.

Authors:  Ras Trokovic; Nina Trokovic; Sanna Hernesniemi; Ulla Pirvola; Daniela M Vogt Weisenhorn; Janet Rossant; Andrew P McMahon; Wolfgang Wurst; Juha Partanen
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

3.  Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate.

Authors:  M Ittman; A Mansukhani
Journal:  J Urol       Date:  1997-01       Impact factor: 7.450

4.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Authors:  Victor D Acevedo; Rama D Gangula; Kevin W Freeman; Rile Li; Youngyou Zhang; Fen Wang; Gustavo E Ayala; Leif E Peterson; Michael Ittmann; David M Spencer
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

5.  Metastatic prostate cancer in a transgenic mouse.

Authors:  J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

Review 6.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

7.  Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.

Authors:  F Yang; D W Strand; D R Rowley
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

8.  FGFR1 and WT1 are markers of human prostate cancer progression.

Authors:  Elizabeth Devilard; Franck Bladou; Olivier Ramuz; Gilles Karsenty; Jean-Philippe Dalès; Gwenaëlle Gravis; Catherine Nguyen; François Bertucci; Luc Xerri; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2006-11-30       Impact factor: 4.430

9.  Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.

Authors:  Sanaz Memarzadeh; Li Xin; David J Mulholland; Alka Mansukhani; Hong Wu; Michael A Teitell; Owen N Witte
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

10.  Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.

Authors:  K Sahadevan; S Darby; H Y Leung; M E Mathers; C N Robson; V J Gnanapragasam
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

View more
  41 in total

1.  Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma.

Authors:  Angela J Yoon; Shuang Wang; Jing Shen; Nicolas Robine; Elizabeth Philipone; Martin W Oster; Albert Nam; Regina M Santella
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  A molecular signature predictive of indolent prostate cancer.

Authors:  Shazia Irshad; Mukesh Bansal; Mireia Castillo-Martin; Tian Zheng; Alvaro Aytes; Sven Wenske; Clémentine Le Magnen; Paolo Guarnieri; Pavel Sumazin; Mitchell C Benson; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Sci Transl Med       Date:  2013-09-11       Impact factor: 17.956

3.  Type 2 Fibroblast Growth Factor Receptor Signaling Preserves Stemness and Prevents Differentiation of Prostate Stem Cells from the Basal Compartment.

Authors:  Yanqing Huang; Tomoaki Hamana; Junchen Liu; Cong Wang; Lei An; Pan You; Julia Y F Chang; Jianming Xu; Chengliu Jin; Zhongying Zhang; Wallace L McKeehan; Fen Wang
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

4.  FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.

Authors:  An Na Seo; Yan Jin; Hee Jin Lee; Ping-Li Sun; Hyojin Kim; Sanghoon Jheon; Kwhanmien Kim; Choon-Taek Lee; Jin-Haeng Chung
Journal:  Virchows Arch       Date:  2014-08-03       Impact factor: 4.064

5.  Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.

Authors:  Michael Grusch; Karin Schelch; Robert Riedler; Eva Reichhart; Christopher Differ; Walter Berger; Álvaro Inglés-Prieto; Harald Janovjak
Journal:  EMBO J       Date:  2014-07-01       Impact factor: 11.598

Review 6.  Roles of FGFR in oral carcinogenesis.

Authors:  Xiaoyan Xie; Zhiyong Wang; Fangman Chen; Yao Yuan; Jiayi Wang; Rui Liu; Qianming Chen
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

Review 7.  Targeting fibroblast growth factor pathways in prostate cancer.

Authors:  Paul G Corn; Fen Wang; Wallace L McKeehan; Nora Navone
Journal:  Clin Cancer Res       Date:  2013-09-19       Impact factor: 12.531

8.  Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.

Authors:  Claire M Faltermeier; Justin M Drake; Peter M Clark; Bryan A Smith; Yang Zong; Carmen Volpe; Colleen Mathis; Colm Morrissey; Brandon Castor; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

9.  Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer.

Authors:  Fang Yang; Yina Gao; Jingshu Geng; Di Qu; Qiuyue Han; Jiping Qi; Gongyan Chen
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

10.  An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.

Authors:  Xiaolu Pan; Xuemin Lu; Xin Lu; Chang-Jiun Wu; Di Zhao; Shan Feng; Yong Zang; Rumi Lee; Sunada Khadka; Samirkumar B Amin; Eun-Jung Jin; Xiaoying Shang; Pingna Deng; Yanting Luo; William R Morgenlander; Jacqueline Weinrich; Shan Jiang; Qing Chang; Nora M Navone; Patricia Troncoso; Ronald A DePinho; Y Alan Wang
Journal:  Cancer Res       Date:  2018-05-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.